Medication 4: MAO-B Inhibitors: Slowing Dopamine Breakdown
Monoamine oxidase B (MAO-B) inhibitors are another class of Parkinson’s disease medications designed to slow the breakdown of dopamine in the brain. By inhibiting the MAO-B enzyme, these drugs help maintain higher dopamine levels, thereby alleviating Parkinson’s symptoms. Common MAO-B inhibitors include selegiline (Eldepryl, Zelapar) and rasagiline (Azilect).
MAO-B inhibitors can be prescribed as a standalone treatment for early-stage Parkinson’s disease or in combination with levodopa for patients in more advanced stages. These medications can help improve motor function and, in some cases, even delay the need for levodopa.
Side effects of MAO-B inhibitors can include insomnia, nausea, and dizziness. Patients taking these medications should also be cautious with their diet and avoid foods high in tyramine, as this can cause dangerous increases in blood pressure. Healthcare providers will carefully monitor patients on MAO-B inhibitors to ensure their safety and adjust their treatment plans as needed. (4)
